
|Videos|March 1, 2016
Dr. Arlene Sharpe on the Discovery and Further Use of the PD-L1 Pathway
Author(s)Arlene Sharpe, MD, PhD
Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Advertisement
Arlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the discovery of the PD-L1 pathway and the importance of the pathway in inhibiting anti-tumor immunity. Sharpe, whose lab aided in the discover of the pathway, says blocking the pathway in order to treat cancers is important because it allows T cells to work better.
Sharpe adds that the pathway was initially tested in both melanoma and lung cancer, which proved the pathway's usefulness in essentially all cancer types.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































